Virtus Investment Advisers Inc. Buys Shares of 34,846 MiMedx Group, Inc. (NASDAQ:MDXG)

Virtus Investment Advisers Inc. bought a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) during the 4th quarter, HoldingsChannel reports. The firm bought 34,846 shares of the company’s stock, valued at approximately $335,000.

Other large investors have also recently made changes to their positions in the company. First Light Asset Management LLC purchased a new stake in MiMedx Group during the 4th quarter worth about $32,168,000. Norges Bank purchased a new stake in shares of MiMedx Group in the fourth quarter worth about $4,020,000. JPMorgan Chase & Co. boosted its position in shares of MiMedx Group by 133.1% in the fourth quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company’s stock valued at $6,668,000 after acquiring an additional 395,739 shares during the period. Meros Investment Management LP purchased a new position in MiMedx Group during the fourth quarter valued at approximately $3,801,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in MiMedx Group by 484.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company’s stock worth $3,487,000 after acquiring an additional 300,433 shares during the period. 79.15% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on MDXG shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 9th.

Insider Buying and Selling

In other news, CEO Joseph H. Capper acquired 200,000 shares of the business’s stock in a transaction dated Friday, May 2nd. The stock was purchased at an average cost of $6.34 per share, for a total transaction of $1,268,000.00. Following the acquisition, the chief executive officer now owns 529,530 shares of the company’s stock, valued at $3,357,220.20. This trade represents a 60.69% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO William Frank Iv Hulse sold 81,446 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares in the company, valued at $3,859,237.20. This trade represents a 14.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 144,018 shares of company stock worth $1,130,312. Corporate insiders own 1.70% of the company’s stock.

MiMedx Group Stock Down 0.6%

Shares of NASDAQ MDXG opened at $7.05 on Monday. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The business has a 50-day moving average of $7.19 and a 200-day moving average of $8.19. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of 12.82 and a beta of 1.85. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. The business had revenue of $88.21 million during the quarter, compared to analysts’ expectations of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Sell-side analysts expect that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.